Vorasidenib Shows Promise in Treating Deadly Brain Tumors.
Vorasidenib, a newly developed drug, has shown promise in prolonging progression-free survival for patients with a subtype of glioma. The drug specifically targets IDH1/2 mutations in recurrent grade 2 glioma, a slow-growing brain tumor often affecting younger individuals. The trial involved 331 patients, with the group treated with Vorasidenib showing significantly longer disease progression-free periods (average of 27.7 months) compared to the placebo group (11.1 months). This study is the first clinical trial to examine a targeted therapy drug specifically designed to treat brain cancer, with Vorasidenib able to cross the blood-brain barrier.